Back to search results

Digital Tool for Type 2 Diabetes Management

This study is testing a new digital tool called "Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool" (also known as iMatter2) for people with Type 2 Diabetes. This tool uses an AI chatbot to send daily text messages with questions about your health, links to educational materials, and personalized motivational messages. The goal is to see if using iMatter2, compared to usual care, can help lower your Hemoglobin A1C (HbA1c) over 12 months. HbA1c is a measure of your average blood sugar levels over the past 2-3 months. You might be able to join if you are 18 or older, have had Type 2 Diabetes for at least 6 months, and your HbA1c has been above 7% in the past year. The study is currently unclear about its recruitment status.

Study design
This study is a randomized controlled trial, meaning participants will be randomly assigned to either use the iMatter2 tool or receive usual care. It aims to enroll 353 participants.
What's involved
If you participate, you would receive daily text messages from an AI chatbot with questions, educational resources, and motivational messages for 12 months. Your HbA1c will be measured at the beginning and at 12 months.
Compensation
Not stated in the trial record.
Follow-up
Your Hemoglobin A1C (HbA1c) will be measured at 12 months after the study begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05884775

Novel Digital Patient-Reported Outcomes Tool for Diabetes Management

Terminated
NAAges 18+InterventionalHealth services
NYU Langone Health
~37 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Hemoglobin A1C (HbA1c)
Measured over Baseline, Month 12

Conditions

Type 2 Diabetes

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Devin Mann · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Fulltime primary care provider (MD/DO, NP) practicing at the participating family health centers or faculty group practices and
Provide care to at least five patients with a diagnosis of T2D
Have a diagnosis of T2D for ≥6 months;
Have uncontrolled T2D defined as HbA1c \>7% documented in the EHR on at least two visits in the past year;
Fluency in English or Spanish;
Be willing to send/receive text messages; and
Be \> 18 years of age.

Exclusion

Refuse or are unable to provide informed consent;
Have acute renal failure, end stage renal disease (ESRD) or evidence of dialysis, renal transplantation, or other ESRD-related services documented in the EHR;
Have significant psychiatric comorbidity or reports of substance abuse (as documented in the EHR);
Are pregnant or planning to become pregnant within 12 months;
Currently participate in another T2D study; or
Plan to discontinue care at the clinic within the next 12 months.

What this trial measures

  • Change in Hemoglobin A1C (HbA1c)Baseline, Month 12

    HbA1c will be extracted from lab data available within the EHR